Ribo Newsroom
-
Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.July 29, 2022 -
Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide TherapeuticsRibocure Pharmaceuticals, the first overseas R&D center of Ribo based in Sweden, announces it will move in and open a clinical trial unit at GoCo Clinic - where both patient care and research will be conducted when it’s ready in the spring of 2023.June 29, 2022 -
Li-Ming Gan, Former VP & Head of Global Clinical Development at AstraZeneca, Joined Ribo as President of Global R&D and CMOSuzhou Ribo Life Science Co., Ltd. recently announced the Prof. Li-Ming Gan, the former Vice President and head of global clinical development for cardiovascular, renal and metabolism area at AstraZeneca CVRM R&D headquarter in Sweden, has joined Ribo and will serve as the President of Global R&D and Chief Medical Officer since 1st of Jan 2February 25, 2022 -
Ribo Completed Two Phase II Clinical Studies in China for Evaluation of Effects of ISIS 449884 in Patients with Type 2 Diabetes Mellitus on Either Life-Style Intervention Only or Metformin Background TreatmentSuzhou Ribo Life Science Co., Ltd. has announced the successful completion of two phase II clinical trials of ISIS 449884, an antisense oligonucleotide（ASO）drug for treatment of Type 2 Diabetes Mellitus (T2DM).February 22, 2022 -
Ribo's siRNA Drug RBD1016 for the Treatment of Chronic Hepatitis B Has Completed a Clinical Study for Safety and Pharmacokinetic Evaluation in Healthy SubjectsRibo Life Science Co., Ltd. (Ribo) recently announced the completion of "A randomized, double-blind, placebo-controlled, single-dose escalating Phase I clinical study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" of its Class 1 siRNA drug for chronic hepatitis B in Australia.January 18, 2022 -
Ribo was selected as one of the "50 Smartest Companies" by MIT Technology ReviewOn Nov. 19, MIT Technology Review unveiled its list of "50 Smartest Companies" (TR50) of 2020 in Suzhou, China. Thanks to the innovative breakthroughs in oligonucleotide therapeutics, Ribo was shortlisted as a manufacturer of innovative drugs and listed as a TR50 smart company.November 20, 2020